Victor S. Lin

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti et al. · Blood · 2020 · 84 citations · Full text

Clonal hematopoiesis, myeloid disorders and <i>BAX</i>-mutated myelopoiesis in patients receiving venetoclax for CLL

Piers Blombery, Thomas E. Lew, Michael A. Dengler et al. · Blood · 2021 · 71 citations · Full text

Hematological Malignancy, Simultaneous Bcl2 Mutations, Oncology +14

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Thomas E. Lew, Victor S. Lin, Edward R. Scheffer Cliff et al. · Blood Advances · 2021 · 70 citations · Full text

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Thomas E. Lew, Mary Ann Anderson, Victor S. Lin et al. · Blood Advances · 2020 · 38 citations · Full text

Attainment Plateaus, Mixed-phenotype Acute Leukemia, Immunology +18

The Last Frontier: Catch Records of White Sharks (Carcharodon carcharias) in the Northwest Pacific Ocean

Heather M. Christiansen, Victor S. Lin, S. Tanaka et al. · PLoS ONE · 2014 · 27 citations · Full text

Northwest Pacific Ocean, Fishery Assessment, Last Frontier +12